CAMBRIDGE, Mass., July 19, 2012 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has obtained CE-marking for its fourth automated, high-throughput molecular test designed and developed for the Abbott m2000 System. The IMDx HSV-1/2 for Abbott m2000 detects Herpes Simplex Virus (HSV) viral DNA and differentiates HSV-1 and HSV-2 in male and female genital or oral lesions and cerebral spinal fluid (CSF).
HSV is the most common cause of genital and oral lesions, but can also invade other human tissue, occasionally causing keratitis, encephalitis, meningitis, and neonatal sepsis. Globally, an estimated 4.0 billion people are currently infected with HSV and the worldwide incidence of HSV-1 infection is considered the second largest, surpassed only by incidences of the common cold.(1)
"We are proud to play a role in easing the global burden of herpes virus infections through rapid and precise diagnostics." Says Dr. Alice Jacobs, MD, Chairman & CEO of IntelligentMDx. "Automated, high-throughput molecular diagnostics are becoming the method of choice for fast and reliable diagnosis of infections. The robust performance and automated nature of the IMDx HSV-1/2 for Abbott m2000 assay can aid in the diagnosis of patients and support faster treatment decisions."
The IMDx HSV-1/2 for Abbott m2000 assay offers a fully automated method for accurate testing of up to 94 patient samples simultaneously in less than 6 hours. Minimal hands-on time is required as results are obtained using a direct swab taken from a symptomatic male or female patient. When compared against clinical samples classified for HSV-1 and HSV-2 using culture and a molecular reference method, the IMDx HSV-1/2 for Abbott m2000 demonstrated 100.0% sensitivity and 97.2% specificity for HSV-1 and 100.0% sensitivity and 98.8% specificity for HSV-2.
The IMDx HSV-1/2 for Abbott m2000 assay is part of a series of infectious disease diagnostic tests designed by IMDx for use on the Abbott m2000 system. The IMDx CE-marked test menu for use on the Abbott m2000 system includes real-time PCR assays for the detection of Group B Streptococcus, vancomycin resistant Enterococci (vanA/ vanB) and toxigenic C. difficile.
This assay is CE-marked and not available for sale in the U.S. or Canada.
(1) Global Industry Analysts, Inc. 2011
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
Copyright©2012 PR Newswire.
All rights reserved